- $766.54m
- $426.60m
- $91.28m
Annual balance sheet for AnaptysBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 394 | 548 | 441 | 391 | 385 |
| Net Total Receivables | — | 0.876 | 1.42 | 6.85 | 40.8 |
| Prepaid Expenses | |||||
| Total Current Assets | 397 | 554 | 447 | 407 | 432 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.13 | 21.8 | 20 | 18.3 | 16.2 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 417 | 643 | 610 | 452 | 484 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 19.8 | 16.1 | 26.1 | 37.4 | 45.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 19.8 | 287 | 348 | 364 | 413 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 397 | 356 | 262 | 88.1 | 70.9 |
| Total Liabilities & Shareholders' Equity | 417 | 643 | 610 | 452 | 484 |
| Total Common Shares Outstanding |